Boehringer Intelheim is expanding its antfibrotics pipeline licencing a first-in-class treatment for fibro-inflammatory diseases from Kyowa Kirin Co. Ltd.
Italian Resalis Therapeutics Srl has baged €10m in a Series A financing led by Sunstone Life Science Ventures to complete a Phase I study for RES-010 in obesity.
Hoffmann-La Roche AG has published details on the mechanism of action of its Phase I antibiotic Zosurabalpin (RG6006) that kills the carbapenem-resistant bug Acinetobacter baumannii.
.
Following its announcement from Oktober 2023 to take over the filgotinib business from Galapagos NV, Bologna-based Alfasigma SpA has signed the €170m deal.
Pharmaceutical giant AstrazZeneca wants to take over the Chinese company Gracell Biotechnologies in order to strengthen its cell therapy projects in a deal worth up to $1.2bn.
Cambridge-based Metrion Biosciences Ltd has secured £3.5m in new equity financing – led by Maven Capital Partners and a £1m contribution from existing investor, Gresham House Ventures.
Swiss LimmaTech Biologics and AbVacc Inc have agreed to co-develop AbVacc’s preclinical Staphylococcus aureus vaccine LBT-SA7 (formerly IBT-V02) in case of Phase I success.
The French Republicans have tabled a bill in the National Assembly aimed at banning the commercialisation of cell-based meat in France.
Lausanne-based Vandria SA has cashed in CHF18m in a Series A financing led by ND Capital to drive clinical development of VNA-318.
Antibiotics specialist Antabio SAS has raised €25m in a Series B financing round with subscriptions from the AMR Action Fund, the EIC Fund and from existing investors.